Joseph Beechem Net Worth

The estimated Net Worth of Joseph M Beechem is at least $4.2 Milion dollars as of 6 May 2024. Mr. Beechem owns over 147,853 units of Nanostring Technologies Inc stock worth over $30,426 and over the last 11 years he sold NSTG stock worth over $2,075,500. In addition, he makes $2,094,840 as Senior Vice President - Research and Development at Nanostring Technologies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Beechem NSTG stock SEC Form 4 insiders trading

Joseph has made over 16 trades of the Nanostring Technologies Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 147,853 units of NSTG stock worth $15,569 on 6 May 2024.

The largest trade he's ever made was exercising 147,853 units of Nanostring Technologies Inc stock on 6 May 2024 worth over $15,569. On average, Joseph trades about 9,367 units every 30 days since 2014. As of 6 May 2024 he still owns at least 288,943 units of Nanostring Technologies Inc stock.

You can see the complete history of Mr. Beechem stock trades at the bottom of the page.

Joseph Beechem biography

Joseph M. Beechem Ph.D. serves as Senior Vice President - Research and Development of the Company. Prior to joining our company, Dr. Beechem held various positions at Life Technologies, a publicly-traded biotechnology tools company, most recently as Vice President, Head of Advanced Sequencing and Head of Global Sequencing Chemistry, Biochemistry and Biophysics from January 2010 to April 2012. From December 2007 to December 2012, he served as Chief Technology Officer of Life Technologies. During his career at Life Technologies, he led the design and development of multiple genetic analysis technologies, the latest advanced SOLiD sequencing technology and the single molecule nano-DNA sequencing technology. Prior to joining Life Technologies, Dr. Beechem was Chief Scientific Officer at Invitrogen, a publicly-traded biotechnology company that acquired Applied Biosystems in November 2008 to form Life Technologies, from August 2003 to December 2007 and Director of Biosciences at Molecular Probes, a biotechnology company acquired by Invitrogen in 2003, from August 2000 to August 2003. Prior to his industry experience, Dr. Beechem led an NIH-funded research laboratory for 11 years as a tenured associate professor at Vanderbilt University. He has authored or co-authored more than 100 peer-reviewed papers in diverse fields such as biomathematics, physics, chemistry, physiology, spectroscopy, diagnostics and biology. Dr. Beechem is also named on nearly 40 U.S. patents or patent applications and has served on a number of editorial and scientific advisory boards. He received a B.S. in Chemistry and Biology from Northern Kentucky University and a Ph.D. in Biophysics from The Johns Hopkins University.

What is the salary of Joseph Beechem?

As the Senior Vice President - Research and Development of Nanostring Technologies Inc, the total compensation of Joseph Beechem at Nanostring Technologies Inc is $2,094,840. There are 2 executives at Nanostring Technologies Inc getting paid more, with R. Bradley Gray having the highest compensation of $7,288,840.

How old is Joseph Beechem?

Joseph Beechem is 62, he's been the Senior Vice President - Research and Development of Nanostring Technologies Inc since 2012. There are 5 older and 10 younger executives at Nanostring Technologies Inc. The oldest executive at Nanostring Technologies Inc is William Young, 75, who is the Independent Chairman of the Board.

What's Joseph Beechem's mailing address?

Joseph's mailing address filed with the SEC is 530 FAIRVIEW AVENUE N, , SEATTLE, WA, 98109.

Insiders trading at Nanostring Technologies Inc

Over the last 11 years, insiders at Nanostring Technologies Inc have traded over $114,083,977 worth of Nanostring Technologies Inc stock and bought 981,722 units worth $9,126,410 . The most active insiders traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus... oraz Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of $4,371. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth $15,569.

What does Nanostring Technologies Inc do?

nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali

Complete history of Mr. Beechem stock trades at Nanostring Technologies Inc

Nanostring Technologies Inc executives and stock owners

Nanostring Technologies Inc executives and other stock owners filed with the SEC include:

• R. Bradley Gray,
  President, Chief Executive Officer, Director
• K. Thomas Bailey,
  Chief Financial Officer
• Joseph Beechem,
  Senior Vice President - Research and Development
• John Brown,
  Senior Vice President - Sales and Marketing
• David Ghesquiere,
  Senior Vice President - Corporate and Business Development
• R. Bradley Gray,
  CEO, Pres & Director
• K. Thomas Bailey M.B.A.,
  Chief Financial Officer
• Dr. Joseph M. Beechem,
  Chief Scientific Officer and Sr. VP of R&D
• J. Chad Brown,
  Sr. VP of Sales & Marketing
• David W. Ghesquiere,
  Sr. VP of Corp. & Bus. Devel.
• William Young,
  Independent Chairman of the Board
• Gregory Norden,
  Independent Director
• Don Kania,
  Independent Director
• Charles Waite,
  Independent Director
• Elisha Finney,
  Independent Director
• Kirk Malloy,
  Independent Director
• Robert Hershberg,
  Independent Director
• Elizabeth Schneider Ph.D.,
  Sr. Global Marketing Mang.
• Dr. Philippa Webster Ph.D.,
  Sr. Principal Scientist
• Dr. Mary Tedd Allen,
  Sr. VP of Strategic Initiatives
• Kathryn Surace-Smith,
  Sr. VP of HR & Legal Affairs and Corp. Sec.
• Douglas S. Farrell,
  VP of Investor Relations & Corp. Communications
• Mark A. Winham,
  Sr. VP of Operations
• Teresa M. Foy,
  Director
• Nicholas Galakatos,
  Director
• Lifesciences Ii, L.P.Clarus...,
  
• Wayne Burns,
  SVP, Operations & Admin
• James A Johnson,
  Chief Financial Officer
• J. Chad Brown,
  SVP, Sales & Marketing
• Mary Tedd Allen,
  SVP, Operations
• Lifesciences Ii, L.P.Clarus...,
  
• Barney Saunders,
  SVP & GM, Life Sciences
• Venture Partners Vi Lpovp V...,
  
• Fisher Jurvetson Fund Vii, ...,
  
• Finny Kuruvilla,
  Director
• Tina Susan Nova,
  Director
• Bruce J. Seeley,
  SVP & GM, Diagnostics
• J Wayne Cowens,
  Chief Medical Officer
• Jennifer Scott Fonstad,
  Director
• Bradford Crutchfield,
  Director
• Janet George,
  Director
• Dana E. Rollison,
  Director
• John D. Gerace,
  Chief Commercial Officer
• Jonathan Todd Garland,
  Chief Commercial Officer